Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.140
-0.010 (-0.47%)
At close: Aug 1, 2025, 4:00 PM
2.120
-0.020 (-0.93%)
After-hours: Aug 1, 2025, 4:10 PM EDT

Oramed Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Oramed Pharmaceuticals.

Price Target: $0.00 (0.00%)
Analyst Consensus: Hold
TargetLowAverageMedianHigh
Pricen/an/an/an/a
Changen/an/an/an/a

Analyst Ratings

According to 1 stock analyst, the rating for Oramed Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

RatingApr '24May '24Jun '24Jul '24Aug '24Sep '24
Strong Buy000000
Buy000000
Hold211111
Sell000000
Strong Sell000000
Total211111

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
HoldReiteratesn/an/aSep 9, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
n/a
HoldReiteratesn/an/aMay 20, 2024
Canaccord Genuity
Canaccord Genuity
Hold
Maintains
$3$2
HoldMaintains$3$2-6.54%May 17, 2023
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Downgrades
n/a
HoldDowngradesn/an/aJan 17, 2023
Canaccord Genuity
Canaccord Genuity
Hold
Downgrades
n/a
HoldDowngradesn/an/aJan 12, 2023
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.07
from -0.48
EPS Next Year
n/a
from -0.07
Fiscal YearFY 2021FY 2021FY 2022FY 2023FY 2024FY 2025
Period EndingAug 31, 2021Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue
2.70M2.71M2.70M1.34M--
Revenue Growth
-0.33%0.33%-0.33%-50.43%--
EPS
-0.78-0.94-0.940.14-0.48-0.07
EPS Growth
------
Forward PE
------
No. Analysts
-----3
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue2025
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth2025
High-
Avg-
Low-

EPS Forecast

EPS2025
High-0.07
Avg-0.07
Low-0.07

EPS Growth

EPS Growth2025
High-
Avg-
Low-
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.